Enhanced Vancomycin Hemodialysis model now available in DoseMeRx!Learn more →

News & Media

Industry Veteran Dr. Howard McLeod Joins the DoseMe Clinical Advisory Board

In this article:

The Clinical Advisory Board (CAB) is a group of prestigious experts advising DoseMe in the pursuit of clinical excellence and governance and we are thrilled to add Dr. Howard McLeod, FASCO, FCCP.

April 23, 2024

Dr. Howard McLeod is an internationally recognized expert in precision medicine, having made novel contributions at the discovery, translation, implementation, and policy levels. He is the Director and Professor at the Utah Tech University Center for Precision Medicine and Functional Genomics and a Precision Medicine Advisor at the Geriatric Oncology Consortium.

“There have been great strides in some areas of precision medicine, but there needs to be a massive change in culture. I am thrilled to join the CAB as I believe dosing is one of the top priorities for standardized practices,” commented McLeod. “I share DoseMe’s vision and passion to bring precision dosing to the forefront of clinical practice and drug development and I look forward to collaborating with some of the best minds in the industry.”

Dr. McLeod has implemented or advised implementation of precision medicine at integrated health systems, academic medical centers, and community practices around the world. Dr. McLeod was a recent member of both the FDA committee on Clinical Pharmacology and the NIH Human Genome Advisory Council.

Howard has published over 600 peer reviewed papers on precision medicine, pharmacogenomics, and clinical pharmacology and continues to work to advance innovative healthcare. “Howard brings a wealth of knowledge that is invaluable, we are incredibly privileged to welcome him aboard,” Sharmeen Roy, Chief Strategy and Science Officer at DoseMe. “On a personal note, I find Howard’s clinical acumen and visionary approach to precision medicine truly inspiring. His involvement is sure to shape our product’s trajectory and spur the critical shift toward precision dosing in healthcare.”

Dr. McLeod has been recognized as a Fellow of both the American Society of Clinical Oncology and the American College of Clinical Pharmacy. He has also been an active Board Member and/or Founder for over a dozen privately held and publicly traded companies.

“Areas of infectious disease have recognized the benefits of dosing with efficacy and minimizing toxicity events, but we can do better,” states McLeod.

HIPAA Privacy Statement | Privacy policy | DoseMe & the GDPR | Copyright © 2012 - 2024 DoseMe Pty Ltd. All Rights Reserved.
DoseMe® is a registered trademark of DoseMe Pty Ltd. DoseMeRx℠ and DoseMe℞℠ are service marks of DoseMe LLC.